Refining Immunogenicity through Intradermal Delivery of Outer Membrane Vesicles against Shigella flexneri in Mice
Open Access
- 29 November 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (23) , 16910
Abstract
Shigellosis remains a global health concern, especially in low- and middle-income countries. Despite improvements in sanitation, the absence of a licensed vaccine for human use has prompted global health organizations to support the development of a safe and effective multivalent vaccine that is cost-effective and accessible for limited-resource regions. Outer Membrane Vesicles (OMVs) have emerged in recent years as an alternative to live attenuated or whole-inactivated vaccines due to their immunogenicity and self-adjuvating properties. Previous works have demonstrated the safety and protective capacity of OMVs against Shigella flexneri infection in mouse models when administered through mucosal or intradermal routes. However, some immunological properties, such as the cellular response or cross-protection among different Shigella strains, remained unexplored. In this study, we demonstrate that intradermal immunization of OMVs with needle-free devices recruits a high number of immune cells in the dermis, leading to a robust cellular response marked by antigen-specific cytokine release and activation of effector CD4 T cells. Additionally, functional antibodies are generated, neutralizing various Shigella serotypes, suggesting cross-protective capacity. These findings highlight the potential of OMVs as a promising vaccine platform against shigellosis and support intradermal administration as a simple and painless vaccination strategy to address this health challenge.Keywords
Funding Information
- Gobierno de Navarra, Spain-Next Generation EU
This publication has 33 references indexed in Scilit:
- Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in EuropeEBioMedicine, 2017
- Effective protection of mice against Shigella flexneri with a new self-adjuvant multicomponent vaccineJournal of Medical Microbiology, 2017
- Development of a high-throughput method to evaluate serum bactericidal activity using bacterial ATP measurement as survival readoutPLOS ONE, 2017
- Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge StudyClinical and Vaccine Immunology, 2017
- Development of a cost-effective vaccine candidate with outer membrane vesicles of a tolA-disrupted Shigella boydii strainVaccine, 2016
- Shigella Isolates From the Global Enteric Multicenter Study Inform Vaccine DevelopmentClinical Infectious Diseases, 2014
- Intradermal Delivery of Shigella IpaB and IpaD Type III Secretion Proteins: Kinetics of Cell Recruitment and Antigen Uptake, Mucosal and Systemic Immunity, and Protection across SerotypesThe Journal of Immunology, 2014
- Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in miceVaccine, 2013
- Progress and pitfalls in Shigella vaccine researchNature Reviews Gastroenterology & Hepatology, 2013
- High Yield Production Process for Shigella Outer Membrane ParticlesPLOS ONE, 2012